Aflibercept
- Product Name
- Aflibercept
- CAS No.
- 862111-32-8
- Chemical Name
- Aflibercept
- Synonyms
- VEGF trap;Aflibercept1;VEGF Trap R1R2;Aflibercept 40mg/ml;Aflibercept (VEGF Trap);Research Grade Aflibercept;Aflibercept iso-osmotic ophthalmic;Research Grade Aflibercept(DHD12629);Aflibercept - approx 40mg/ml solution
- CBNumber
- CB52498796
- Molecular Formula
- C4318H6788N1164O1304S32
- Formula Weight
- 0
- MOL File
- Mol file
Aflibercept Property
- form
- Liquid
- color
- Colorless to light yellow
Safety
- Hazardous Substances Data
- 862111-32-8(Hazardous Substances Data)
N-Bromosuccinimide Price
- Product number
- BA165580
- Product name
- Aflibercept
- Packaging
- 1mg
- Price
- $600
- Updated
- 2021/12/16
Aflibercept Chemical Properties,Usage,Production
Description
In November 2011, the U.S. FDA approved the recombinant fusion protein aflibercept, administered as an intravitreal injection, for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD). Aflibercept differs from these agents in that it acts as a soluble decoy receptor that binds all VEGF isoforms more tightly than their native receptors, thereby diverting VEGF from its normal function. Aflibercept consists of a fusion of the second Ig domain of human VEGF receptor 1 and the third Ig domain of human VEGF receptor 2 fused to the constant region of (Fc) of human immunoglobulin G1. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kDa and glycoside molecular weight of 18 kDa. It is produced in recombinant Chinese hamster ovary (CHO) cells that overexpress the fusion protein. Aflibercept has subpicomolar affinity for VEGF-A (KD=0.66 pM for VEGF-A165 and 0.19 pM for VEGF-A121), the major driver of pathological angiogenesis and vascular leak in wet AMD.19 Ranibizumab and bevacizumab bind VEGF-A165 with lower affinity (KD=20.6 and 35.1 pM, respectively).
Originator
Regeneron Pharmaceuticals (United States)
Uses
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease[1][2][3].
brand name
Eylea
in vivo
Aflibercept (10 mg/kg; 3 h post-middle cerebral artery occlusion (MCAO)) reduces stroke-induced VEGF-A and VEGFR2 expression, and brain edema, and BBB disruption and improves poststroke survival in obese mice[2]. Aflibercept (18.2 mg/kg and 36.4 mg/kg; i.v. once) affects BP, ROS and eNOS production in mice[3].
| Animal Model: | Male C57BL/6 mice[3] |
| Dosage: | 18.2 mg/kg and 36.4?mg/kg |
| Administration: | Intravenous injection; 18.2 mg/kg and 36.4?mg/kg once |
| Result: | Rapidly and dose-dependently elevated BP in mice and markedly impaired endothelial-dependent relaxation (EDR) and resulted in NADPH oxidases 1 (NOX1)- and NADPH oxidases 4 (NOX4)-mediated generation of ROS, decreased the activation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) concurrently with a reduction in nitric oxide (NO) production and elevation of ET-1 levels in mouse aortas. |
References
[1] Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98(10):1448-52. DOI:10.1136/bjophthalmol-2014-305105
[2] Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648. DOI:10.1161/STROKEAHA.121.034362
[3] Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42(9):1437-1448. DOI:10.1038/s41401-020-00569-1
Aflibercept Preparation Products And Raw materials
Raw materials
Preparation Products
Aflibercept Suppliers
- Tel
- +86-21-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6003
- Advantage
- 61
- Tel
- 1-(800)-881-8210
- Fax
- 615-250-9817
- inquiries@lgmpharma.com
- Country
- United States
- ProdList
- 2123
- Advantage
- 70
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- 0571-86403260 86403970
- Fax
- 0571-86403970
- lucky@lkbiology.com
- Country
- China
- ProdList
- 243
- Advantage
- 58
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4757
- Advantage
- 55
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-31433387 15618786686
- Fax
- QQ:1369748377
- sales@rechemscience.com
- Country
- China
- ProdList
- 2989
- Advantage
- 58
- Tel
- +86-0571-85134551
- Fax
- 008657185134895
- sales@afinechem.com
- Country
- China
- ProdList
- 15109
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 021-50967598 02150967598
- sales@abmole.cn
- Country
- China
- ProdList
- 4494
- Advantage
- 58